Johnson & Johnson Exceeds Q3 Earnings Expectations and Raises Full-Year Guidance
Johnson & Johnson (ticker: JNJ) reported third-quarter earnings that exceeded expectations, with non-GAAP EPS of $2.59, beating estimates by $0.06. Revenue came in at $25.4 billion, matching forecasts. The company also raised its full-year adjusted EPS guidance for 2026. The positive results were driven by strong performance across several business segments and long-term data from the drug Tremfya showing sustained efficacy in treating Crohn's disease over three years. Analysts have noted that while Johnson & Johnson faces future patent cliffs, it is already working on replacements to maintain growth momentum. Johnson & Johnson outperformed peers like AbbVie during a recent healthcare dividend review and continues to be seen as having strong catalysts for long-term value despite maintaining a 'Hold' rating from some analysts.
Topics: earnings healthcare pharmaceuticals